Coronado Biosciences Debuts on Nasdaq, Moves Two Lead Drugs Forward

The path to becoming a publicly listed company chosen by Coronado Biosciences was anything but conventional, but it seems to be working for the biotech startup. After raising $47.4 million privately over the last year, the company filed a Form 10 with the SEC so it could become a public company by registering all its private shares as common stock, rather than undergoing a typical, underwritten IPO.
Xconomy